Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

New radioligands tested for assessment of AD in living subjects

Jan. 21, 2014

Preliminary trial results provided for selinexor in colorectal cancer

Jan. 21, 2014

Nektar Therapeutics reviews product development status for 2014

Jan. 21, 2014

Simtuzumab well tolerated in phase I and II trials

Jan. 21, 2014

Lanreotide autogel/depot reduces carcinoid syndrome rescue therapy in ELECT trial

Jan. 21, 2014

Safety issues noted in phase I study of cabazitaxel in gastric adenocarcinoma

Jan. 21, 2014

Karyopharm targets PAK-4 in pancreatic cancer

Jan. 20, 2014

Development of a novel class of tau ligands for medical imaging of AD

Jan. 20, 2014

Phase II results show vismodegib is well tolerated in patients with mPDA

Jan. 20, 2014

Nab-paclitaxel shows promise in esophageal squamous cell carcinoma trial

Jan. 17, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...